https://scholars.lib.ntu.edu.tw/handle/123456789/470790
Title: | Postchemoradiotherapy pathologic stage classified by the American joint committee on the cancer staging system predicts prognosis of patients with locally advanced esophageal squamous cell carcinoma | Authors: | JHE-CYUAN GUO Ta-Chen Huang CHIA-CHI LIN MIN-SHU HSIEH Chang C.-H. PEI-MING HUANG JANG-MING LEE Feng-Ming Hsu CHIA-HSIEN CHENG HSIU-PO WANG KUN-HUEI YEH ANN-LII CHENG CHIH-HUNG HSU |
Issue Date: | 2015 | Publisher: | Lippincott Williams and Wilkins | Journal Volume: | 10 | Journal Issue: | 10 | Start page/Pages: | 1481-1489 | Source: | Journal of Thoracic Oncology | Abstract: | Introduction: To determine whether the postchemoradiotherapy (post-CRT) pathologic stage predicts the outcomes of patients with locally advanced esophageal squamous cell carcinoma (ESCC) undergoing preoperative CRT followed by surgery. Methods: From three phase II trials of preoperative CRT for locally advanced ESCC, 140 patients were included. Preoperative CRT comprised twice weekly paclitaxel and cisplatin-based regimens and 40-Gy radiotherapy in 20 fractions. The post-CRT pathologic stage was classified according to the American Joint Committee on Cancer, 7th edition staging system. The prognostic effects of clinicopathologic factors were analyzed using Cox regression. Results: With a median follow-up of 61.9 months, the median progression-free survival (PFS) and overall survival (OS) of the entire cohort were 24.5 and 30.9 months, respectively. The post-CRT pathologic stage was 0 in 34.5%, I in 12.9%, II in 29.3%, III in 13.6%, and ypT0N1-2 in 6.4% of the patients. The median PFS was 47.2, 25.9, 16.0, 9.4, and 15.1 months, and the median OS was 57.4, 34.1, 26.2, 14.1, and 17.6 months for patients with post-CRT pathologic stage 0, I, II, III, and ypT0N1-2, respectively. In multivariate analysis, performance status (p < 0.001), tumor location (p = 0.016), and extranodal extension (p = 0.024) were independent prognostic factors for PFS, whereas performance status (p < 0.001) and post-CRT pathologic stage (p = 0.027) were independent prognostic factors for OS. Conclusions: The post-CRT pathologic stage classified by American Joint Committee on Cancer, 7th edition staging system predicted the survival of locally advanced ESCC patients who underwent preoperative paclitaxel and cisplatin-based CRT followed by esophagectomy. ? 2015 by the International Association for the Study of Lung Cancer. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84942508462&doi=10.1097%2fJTO.0000000000000651&partnerID=40&md5=32869c6c850026803933bef54e0ade0f https://scholars.lib.ntu.edu.tw/handle/123456789/470790 |
ISSN: | 1556-0864 | DOI: | 10.1097/JTO.0000000000000651 | SDG/Keyword: | cetuximab; cisplatin; fluorouracil; folinic acid; paclitaxel; adjuvant chemoradiotherapy; adult; advanced cancer; aged; Article; cancer patient; cancer prognosis; cancer radiotherapy; cancer staging; cancer surgery; cancer survival; drug megadose; endoscopic echography; esophageal squamous cell carcinoma; esophagogastroduodenoscopy; esophagus resection; female; follow up; human; major clinical study; male; middle aged; multimodality cancer therapy; outcome assessment; overall survival; phase 2 clinical trial; positron emission tomography; priority journal; progression free survival; surgical patient; treatment duration; cancer staging; Carcinoma, Squamous Cell; chemoradiotherapy; Esophageal Neoplasms; pathology; prognosis; United States; world health organization; Adult; Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; United States; World Health Organization |
Appears in Collections: | 病理學科所 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.